Table 6.

Exposure to rufinamide and treatment withdrawal due to overall adverse events: Meta-analysis

Study characteristics			Rufinamide		Placebo		Risk ratio	Weight
Study No.	Authors	Year	Events	Total	Events	Total	M-H, Fixed, 95% CI	%
1	Biton et al. [11]	2011	27	176	11	180	2.51 [1.29, 4.90]	37.7
2	Brodie et al. [10]	2009	21	156	5	157	4.23 [1.64, 10.93]	17.3
3	Elger et al. [14]	2010	29	262	9	133	1.64 [0.80, 3.35]	41.4
4	Glauser et al. [5]	2008	6	74	0	64	11.27 [0.65, 196.18]	1.9
5	Palhagen et al. [15]	2001	2	25	0	25	5.00 [0.25, 99.16]	1.7
Total events			85	693	25	559	2.65 [1.74, 4.03]	100

Heterogeneity: χ = 3.85, d.f. = 4 (P = 0.43); I² = 0%. Test for overall effect: Z = 4.57 (P < 0.00001).